UT 231B
Alternative Names: UT 231; UT-231BLatest Information Update: 19 Jun 2007
At a glance
- Originator Pfizer; University of Oxford
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis C
Most Recent Events
- 19 Jun 2007 No development reported - Phase-II for Hepatitis C in USA (PO)
- 31 Jul 2003 Phase-II clinical trials in Hepatitis C in USA (PO)
- 07 May 2003 Synergy Pharmaceuticals has been acquired by Webtronics